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Abstract
Background: Detecting epidermal growth factor receptor (EGFR) activating mutations in plasma could guide EGFR-
tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non-small cell lung cancer (NSCLC). However, dynamic
quantitative changes of plasma EGFR mutations during the whole course of EGFR-TKI treatment and its correlation
with clinical outcomes were not determined. The aim of this study was to measure changes of plasma EGFR L858R
mutation during EGFR-TKI treatment and to determine its correlation with the response and resistance to EGFR-TKI.
Methods: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to
2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901).
Totally, 256 patients were enrolled in CTONG0901 and randomized to receive erlotinib or gefitinib. One hundred and
eight patients harbored L858R mutation in their tumors and 80 patients provided serial blood samples as pre-planned
scheduled. Serial plasma L858R was detected using quantitative polymerase chain reaction. Dynamic types of plasma
L858R were analyzed using Ward’s hierarchical clustering method. Progression-free survival (PFS) and overall survival
(OS) were compared between different types.
Results: As a whole, the quantity of L858R decreased and reached the lowest level at the time of best response to
EGFR-TKI. After the analysis of Ward’s hierarchical clustering method, two dynamic types were found. In 61 patients,
L858R increased to its highest level when disease progressed (ascend type), while in 19 patients, L858R maintained a
stable level when disease progressed (stable type). Median PFS was 11.1 months (95 % CI, 6.6–15.6) and 7.5 months
(95 % CI, 1.4–13.6) in patients with ascend and stable types, respectively (P = 0.023). Median OS was 19.7 months
(95 % CI, 16.5–22.9) and 16.0 months (95 % CI, 13.4–18.5), respectively (P = 0.050).
Conclusions: This is the first report finding two different dynamic types of plasma L858R mutation during
EGFR-TKI treatment based on a prospective randomized study. Different dynamic types were correlated with
benefits from EGFR-TKI. The impact of plasma L858R levels at disease progression on subsequent treatment
strategy needs further exploration.
Trial registration: ClinicalTrials.gov, NCT01024413
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Background
Epidermal growth factor receptor (EGFR) activating muta-
tions in the tyrosine kinase domain serve as predictive
biomarkers for EGFR-tyrosine kinase inhibitor (EGFR-
TKI) treatment outcome for patients with advanced non-
small cell lung cancer (NSCLC) [1–6]. However, due to
the invasive procedures required to obtain tumor tissues,
not all patients can provide enough high-quality tissues
for EGFR mutation analysis. Circulating free DNA
(cfDNA) in plasma provides a noninvasive substitute for
tumor tissues [7]. Several studies have reported a concord-
ance rate between tumor and plasma >90 %, even reaching
97 %, demonstrating the feasibility of detecting EGFR mu-
tations in cfDNA [8–10]. EGFR mutation status detection
in cfDNA has been approved by the European Society for
Medical Oncology and by China to be used with EGFR-
TKI treatment for NSCLC [11, 12].
In addition to providing pretreatment information,
plasma-based EGFR mutation detection makes it pos-
sible to monitor dynamic changes in this mutation
during treatment. Several studies have reported a quanti-
tative change in EGFR mutations during EGFR-TKI
treatment by comparing pre- and post-treatment plasma,
in which various types of plasma EGFR mutations were
found [13–15]. The quantity of the plasma EGFR muta-
tion sometimes decreases, or sometimes decreases
slowly or rapidly. Patients whose plasma EGFR muta-
tions decrease rapidly usually exhibit a better response
to EGFR-TKI treatment [15]. However, these studies
were not based on prospective clinical trials; therefore,
the number of patients who had serial plasma specimens
tested during EGFR-TKI treatments was limited, and
very few plasma specimens were collected as part of a
pre-planned schedule. The only recent study on plasma
EGFR mutation changes based on a prospective clinical
trial was reported by Mok et al. [16]. In this phase III
trial (FASTACT-2), patients received gemcitabine/platinum
plus sequential erlotinib or placebo. EGFR mutation-
specific cfDNA levels decreased at cycle 3 and increased at
the time of disease progression. Positive plasma EGFR
mutant DNA at cycle 3 predicted a worse clinical outcome.
In this study, the treatment was chemotherapy plus EGFR-
TKI or placebo, not EGFR-TKI, and there was no informa-
tion on the plasma EGFR mutation at other time points ex-
cept at baseline, cycle 3, and at disease progression. The
dynamic types of plasma EGFR mutations during the
whole course of EGFR-TKI treatment and its correlation
with clinical outcomes were not determined.
The present study was a pre-planned exploratory ana-
lysis of a randomized phase III trial comparing erlotinib
with gefitinib treatment in advanced NSCLC patients
containing EGFR mutations in tumor tissues (The Chin-
ese Thoracic Oncology Group 0901, CTONG0901,
NCT01024413). Serial plasma samples were collected as
a pre-planned schedule, and the EGFR L858R mutation
was detected using quantitative polymerase chain reac-
tion (qPCR). We quantitatively measured changes in the
L858R mutation and determined its correlation with
clinical outcomes.
Methods
Study design and treatment
Serial plasma samples were taken from patients enrolled in
CTONG0901, a single-center trial designed to compare er-
lotinib with gefitinib treatment in patients with advanced
NSCLC who had EGFR activating mutations in tumor tis-
sues. Eligible patients were over 18 years of age and had
histologically or cytologically confirmed stage IIIB or IV
NSCLC (AJCC/UICC, version 6) with EGFR activating mu-
tations in their tumor samples, tested by direct sequencing
as previously described [17]. Previously untreated patients
and those receiving any type of systemic chemotherapy
regimen without prior exposure to any EGFR-TKI were
recruited. Eligible patients were 1:1 randomized to receive
erlotinib (150 mg, po, qd) or gefitinib (250 mg, po, qd)
until disease progression, unacceptable toxicity, or discon-
tinuation of treatment due to other reasons. The primary
endpoint was progression-free survival (PFS). Secondary
endpoints included objective response rate (ORR), overall
survival (OS), disease control rate (DCR), post-progression
survival (PPS), safety, and biomarker analyses.
This trial was conducted in Guangdong Lung Cancer
Institute of Guangdong General Hospital. It adhered to
the Declaration of Helsinki and the Good Clinical Prac-
tice guidelines. The protocol was approved by the ethics
committee at Guangdong General Hospital (committee’s
reference number: GDREC [2009]011). All patients pro-
vided written informed consent for participation, with
separate consent obtained for tumor specimens and/or
blood samples for biomarker analyses. The pre-planned
schedule for collecting serial blood samples during the
course of EGFR-TKI treatment included baseline, 1 week
after treatment, 1 month after treatment, and every
8 weeks until the appearance of disease progression. At
each time point, 8 mL of blood was collected. Except for
1 week after treatment, other time points were exactly
the same day when patients underwent computerized
tomography (CT) scans for tumor response evaluation.
Tumor response was evaluated according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST),
version 1.1. The resistance was defined as disease pro-
gression according to RECIST, and the best response
was the greatest reduction in tumor burden.
Biomarker analyses
Blood samples were collected in tubes containing EDTA
according to a fixed schedule. Plasma was immediately
separated from blood cells by centrifugation at 3000 rpm
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at 4 °C for 5 min. Supernatants were collected and
stored at −80 °C until assays were performed. cfDNA
was isolated from 4 mL plasma using a QIAamp DNA
blood mini kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. To increase the testing
sensitivity, we repeated the isolation five times and then
pooled and concentrated the cfDNA from a total of
4 mL plasma for mutation testing.
We analyzed plasma only from patients containing the
L858R mutation. Quantitative analyses of the L858R mu-
tation and the endogenous reference gene antitrypsin in
the cfDNA were performed by qPCR using the Roche
LightCycler® 480 real-time PCR system (Roche Life
Science, Penzberg, Germany) under the following condi-
tions: 95 °C for 10 min for 1 cycle followed by 95 °C for
15 s and 60 °C for 1 min for 50 cycles. An L858R target
assay and human antitrypsin primers with the same
amplification efficiency were developed by Applied Bio-
systems (Foster City, CA, USA). Sequences of the L858R
mutation primers were as follows: forward primer,
GCAGCATGTCAAGATCACAGATTT, reverse primer,
CCTCCTTCTGCATGGTATTCTTTCT; MGB-probe,
FAM-CAGTTTGGCCCGCCCA; antitrypsin forward pri-
mer, GACACCGAAGAGGCCAAGAA, reverse primer,
GAAGATGTAATTCACCAGAGCAAAAA; and MGB-
probe, FAM-TGTGTCTCTGTCAAGCTCCTTGAC. The
qPCR mixture contained 5 μL 2× LightCycler® 480 Probes
Master (Roche Life Science), 0.25 μL primer mix, TaqMan®
Probe Assay (Applied Biosystems), 1.75 μL nuclease-free
water, and 3 μL sample DNA or calibrator or H2O (for the
no template control). Each sample was run in duplicate.
The differences between replicates were lower than 2 cycle
thresholds. If the result from one sample did not meet
this criterion, the procedure was repeated. DNA from
NCI-H1975 cells (harboring L858R mutation) was
used as positive control. Human reference genomic
DNA (catalog G1471, Promega Corporation, Madison,
WI) was used as negative control. PCR grade H2O was
the non-template control. Two wells of positive con-
trols, two wells of negative control, and two wells of
non-template control were included in every run. A
mixture of plasma DNA with the L858R mutation was
used for calibration. The level of the L858R mutation
was normalized to that of the antitrypsin gene. The
relative L858R copy number of each plasma sample
was calculated as follows: R (L858R copy number) = 2
− [(Ct sample L858R − Ct sample antitrypsin) − (Ct CalibratorL858R −
Ct calibrator antitrypsin)].
In plasma at the time of disease progression, we
tested the exon 20 T790M mutation using a T790M
mutation detection kit (Amoy Diagnostics, Xiamen,
China) according to the principle of amplification
refractory mutation system (ARMS) as previously de-
scribed [17].
Statistical analyses
The plasma L858R copy number is described as the
median range. Ward’s hierarchical clustering method
was used to categorize the dynamic types of L858R.
Based upon the schedule of CT scans, we selected seven
time points for Ward’s hierarchical clustering analyses:
baseline, 1 week after baseline, 8 weeks before the best
response, the best response, 8 weeks after the best re-
sponse, 8 weeks before disease progression, and disease
progression. If a patient progressed early on during
treatment and there were not seven time points available
for analysis, the available time points were put on corre-
sponding points of the model and the missing time
points were supplemented by expectation maximum to
maintain the stability of Ward’s hierarchical clustering
analyses. The entire population was classified into differ-
ent groups according to Ward’s hierarchical clustering
analyses. The quantities of L858R mutations between
groups were compared by unequally spaced repeated
measures design analysis of variance (ANOVA). The ra-
tio of change of L858R quantity from baseline to disease
progression (r) was calculated as (quantity of L858R at
disease progression − quantity of L858R at baseline)/
(quantity of L858R at baseline). Cut point of r to separ-
ate different groups was analyzed using maximally se-
lected rank statistics by R software. Constituent ratio of
EGFR T790M and two kinds of EGFR-TKIs between
groups were compared by chi-square or continuity cor-
rection tests. PFS was defined as the time from the date
of randomization to that of disease progression or of
death from any cause. OS was measured from the date
of randomization to the date of death from any cause.
PPS was measured from the date of disease progression
to the date of death from any cause. Survival was esti-
mated using the Kaplan-Meier method and is expressed
as a median value with a range and a two-sided 95 %
confidence interval (CI). A two-sided log-rank test was
used to compare survival between groups. The multi-
variate Cox proportional hazards regression model
(alpha = 0.05) was used to evaluate independent predict-
ive factors associated with PFS. A two-sided P value <.05
was considered statistically significant. SPSS version 17.0
(SPSS, Inc., Chicago, IL) software was used.
Results
Patient characteristics
From December 2009 to July 2014, a total of 256 pa-
tients were enrolled in CTONG0901. One hundred and
eight patients harbored L858R mutation in their tumors
tested by Sanger sequencing, and 105 patients provided
blood samples, with 25 patients providing samples only
at one or two time points and 80 patients providing ser-
ial blood samples as scheduled. The levels of plasma
L858R were therefore tested in 80 patients. The study
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flow diagram is in Fig. 1. Their characteristics are sum-
marized in Additional file 1: Table S1.
Dynamic types of plasma L858R mutations
The L858R mutation was tested by qPCR in serial
plasma samples from 80 patients at each time point, as
scheduled. This mutation was detected in all plasma
samples. As a whole, the quantity of plasma L858R de-
creased and reached the lowest level at the time of best
response to EGFR-TKI treatment and then increased to
its highest level when the disease progressed (Fig. 2a). By
using Ward’s hierarchical clustering analysis, 80 patients
were classified into two groups according to their type
of change. The most dramatic difference between the
two groups was, in one group, the quantity of L858R
increased to its highest level at the time of disease pro-
gression (ascend type, group A, n = 61), while in the
other group, the quantity of L858R did not increase and
maintained a stable level as the disease progressed
(stable type group S, n = 19) (Fig. 2b). Baseline character-
istics of patients in two groups are shown in Table 1.
ANOVA analyses showed that the effect of time was sig-
nificant (F = 4.98, P < 0.01); the interaction of time and
group was significant (F = 11.97, P < 0.01); over time, the
quantity of plasma L858R copy number showed a
linearly increasing trend (F = 23.97, P < 0.01); and the
between-group test indicated that the variable group was
not significant (F = 3.35, P = 0.071). The estimated cut
point of r was 1.07 (M = 3.5877, P = 0.0063), which
meant, compared with the quantity of L858R at baseline,
the quantity at disease progression increased by more
than 1.07 times which was the ascend type and increased
by less than 1.07 times was the stable type. ANOVA ana-
lyses showed that the quantity of plasma L858R over
time had no significant difference between patients re-
ceiving erlotinib and those receiving gefitinib (F = 0.160,
P = 0.690). Furthermore, chi-square test showed that the
constituent ratio of the ascend type and the stable type
in patients who received erlotinib or gefitinib had no
significant difference, either (P = 0.946).
Clinical outcomes
The cutoff date was October 22, 2015, and the median
follow-up time was 20.7 months. In 80 patients, the PFS
endpoint was observed in 79 patients (98.8 %), and 70
patients died (87.5 %). The median PFS was 10.4 months
(95 % CI, 9.1–11.8), and the median OS was 18.6 months
(95 % CI, 16.4–20.8) (Fig. 3). In group A, the median
PFS was 11.1 months (95 % CI, 6.6–15.6), while in group
S, it was 7.5 months (95 % CI, 1.4–13.6); the difference
was statistically significant (HR = 0.55, 95 % CI, 0.32–
0.93, P = 0.023) (Fig. 3a). Median OS showed a margin-
ally statistical increase in group A (19.7 months, 95 %
CI, 16.5–22.9 vs. 16.0 months, 95 % CI, 13.4–18.5, HR =
0.59, 95 % CI, 0.34–1.01, P = 0.050) (Fig. 3b). Median
PPS was 5.5 months (95 % CI, 1.5~9.5) and 5.8 months
(95 % CI, 2.9~8.6) (HR = 0.97, 95 % CI, 0.57–1.64, P =
0.898), respectively. The subsequent therapy was well-
balanced between the two groups (Additional file 1:
Table S2). There was no significant difference in median
OS between groups when patients received subsequent
best support care, or chemotherapy and/or local treat-
ment. However, for patients who received subsequent
other EGFR-TKIs (11 in group A, four in group S), the
median OS differed significantly (38.2 months, 95 % CI,
8.9–67.5, vs. 15.8 months, 95 % CI, 2.3–29.2, P = 0.034)
(Additional file 1: Table S3). The subsequent EGFR-TKIs
included erlotinib, gefitinib, or icotinib which is a do-
mestic first-generation EGFR-TKI in China. No patients
received second- or third-generation EGFR-TKIs. The
following variants were included in the multivariate Cox
proportional hazards regression model: age (≥65, <65),
pathology (adenocarcinoma, non-adenocarcinoma), weight
loss (<5 %, ≥5 %), smoking status (never a smoker, smoker),
family history of cancer (yes, no), Eastern Cooperative On-
cology Group performance status (0–1, ≥2), line of EGFR-
TKI therapy (first line, second line, or further), EGFR-TKI
Randomly assigned 
(n=256) 
EGFRexon 19 mutation subgroup
(n=148) 
EGFRexon 21 mutation subgroup (n=108) 
Did not  provide any blood 
samples (n=3) 
Provided blood samples only at
one or two time points (n=25)
Provided serial blood samples as
schedule (n=80)
Progressive disease (n=79)
Continued treatment at data cut-off (n=1)
Data cut-off: Oct 22, 2015
Fig. 1 CONSORT diagram
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(gefitinib, erlotinib), and dynamic types of plasma L858R
(group A, group S). The results showed that adenocarcin-
oma, PS 0–1, and group A were independent predictive
factors associated with better PFS. Details are in
Table 2.
In 80 patients, 78 plasma samples at disease progres-
sion were tested for the T790M mutation and T790M
was found in 17 samples, 11 samples in group A and six
samples in group S (P = 0.305). There was no significant
difference between patients with and without T790M
in terms of PFS of EGFR-TKI treatment or post-
progression survival (PPS) after EGFR-TKI treatment
(Additional file 1: Table S4).
Discussion
To our knowledge, this is the first report describing dy-
namic quantitative changes in plasma L858R amount
during the whole course of EGFR-TKI treatment based
on a prospective study. For the first time, we found that
there were two different dynamic types of plasma L858R
mutation during EGFR-TKI treatment. In the ascend
type, the quantity of the L858R mutation increased to its
highest level at disease progression, while in the stable
type, the quantity of the L858R mutation did not in-
crease and maintained a stable level at disease progres-
sion. Compared with the quantity of L858R at baseline,
the quantity at disease progression increased by more
than one time was the criteria for separating the two
groups. The ascend type was associated with more
therapeutic benefit from EGFR-TKI treatment than the
stable type. Our results show, for the first time, that the
entire L858R mutation population can be divided into
two subtypes according to quantitative changes of the
plasma L858R mutation.
In the present study, patients with different dynamic
types achieved different benefits from EGFR-TKI treat-
ment. However, the change of quantity of L858R muta-
tion in cfDNA was not a useful predictive biomarker
along the course of EGFR-TKI treatment because the
difference of L858R mutation level was found until
a
b
Fig. 2 Dynamic change of plasma L858R mutation and tumor burden during EGFR-TKI treatment. a In total 80 patients, the quantity of L858R
decreased to its lowest level at the time of best response to EGFR-TKI treatment, and then increased to its highest level when the disease
progressed. b Using Ward’s hierarchical clustering analysis, 80 patients were classified into two groups according to their type of change. In one group,
the quantity of L858R increased to its highest level at the time of disease progression (ascend group), while in the other group, the quantity of L858R
did not increase and maintained a stable level as the disease progressed (stable group)
Zhou et al. Journal of Hematology & Oncology  (2016) 9:86 Page 5 of 8
disease progression. Therefore, from this result, moni-
toring the dynamic change of EGFR activating mutation
during EGFR-TKI treatment had low clinical predictive
value. Two different dynamic types found in this study
demonstrated that the EGFR mutation positive popula-
tion could be divided into two subtypes. These two sub-
types were correlated with different benefit from EGFR-
TKI treatment and showed different dynamic character-
istics of plasma EGFR activating mutation when disease
progressed. The findings warrant further studies to ex-
plore the molecular mechanisms for the change of EGFR
mutation in plasma. Genomic information from next-
generation sequencing (NGS) might contribute to find
the changes of predominant clones and the changes of
other relative genes when disease progressed. Further-
more, the level of plasma EGFR mutation at disease
progression might potentially influence subsequent
treatment strategy. Our subsequent treatment analyses
showed that patients with high levels of plasma L858R
at disease progression achieved greater benefit from sub-
sequent other first generation EGFR-TKIs than those
with low levels of the L858R mutation. Better subse-
quent strategy might be made by combining the level of
plasma EGFR activating mutation and resistant genetic
information when disease progressed.
The EGFR exon 19 deletion and the exon 21 L858R
mutations are the most common activating mutations.
Patients whose tumors are characterized by these two
mutations can achieve dramatic benefits from EGFR-
TKI treatment. They are therefore considered typical
activating mutations. However, an increasing number of
studies have reported that two subtypes of patients
achieve different benefits from EGFR-TKI treatment
[18–20]. The clinical trial CTONG0901, on which our
exploratory study was based, started in 2009 and it was
originally designed to compare the efficacy of gefitinib
or erlotinib treatment in patients only harboring the
EGFR L858R mutation. After 6 months, the protocol
was amended to enroll patients with either exon 19 dele-
tion or exon 21 L858R mutation (Additional file 2).
Therefore, we separated the exploration for plasma
L858R mutation from exon 19 deletion. The present
study only focused on L858R mutation, and our future
plan is to explore the plasma exon 19 deletion to valid-
ate the result of L858R mutation. Another reason why
we focused on L858R mutation in this study was that
exon 19 deletion was more complex to be quantitatively
detected than exon 21 L858R. More sensitive method
was needed to quantitatively detect exon 19 deletion. In
2009 when the CTONG0901 trial was initiated, we used
the qPCR for quantitative analyses of plasma L858R mu-
tations. The sensitivity of qPCR for reliable mutational
analysis is minimum 1~5 % of mutant alleles in a wild-
type background [21–23]. Enough cfDNA from enrolled
advanced NSCLC patients harboring relatively high
abundance EGFR mutation in their tumors contributed
to the high sensitivity in this study [17]. In the future,
other testing methods, for example, droplet digital PCR
or next generation sequencing, should be considered.
There are some limitations to the present study.
We only detected T790M in the plasma at the time
of disease progression by ARMS, which was the most
commonly used method for detecting EGFR mutation
when the study was designed. The sensitivity of ARMS de-
tecting T790M was relatively low and only 17 out of 78
patients (22 %) were found to be T790M positive. We
tried to detect the quantity of T790M mutation by
qPCR during EGFR-TKI treatment but failed, and we
could not do droplet digital PCR or beaming digital
PCR at that time, which is more sensitive than qPCR or
Table 1 Baseline characteristics of patients in the ascend group







Male 30 (49.2) 7 (36.8)
Female 31 (50.8) 12 (63.2)
Age (median, range) 62 (40~84) 69 (40~84) 0.362
Body weight loss 1.000
<5 % 58 (95.1) 19 (100.0)
≥5 % 3 (4.9) 0 (0.0)
Smoking status 0.401
Never-smokers 41 (67.2) 15 (78.9)
Smokers 20 (32.8) 4 (21.1)
ECOG PS 1.000
0~1 58 (95.1) 18 (94.7)
≥2 3 (4.9) 1 (5.3)
Pathology 1.000
Adenocarcinoma 58 (95.1) 18 (94.7)
Non-adenocarcinoma 3 (4.9) 1 (5.3)
Clinical stage 1.000
IIIB 1 (1.6) 0 (0.0)
IV 60 (98.4) 19 (100.0)
Line of EGFR-TKI 0.371
First-line 36 (59.0) 9 (47.4)
≥Second-line 25 (41.0) 10 (52.6)
EGFR-TKI 0.946
Erlotinib 23 (37.7) 7 (36.8)
Gefitinib 38 (62.3) 12 (63.2)
Basic level of plasma
L858R mutation
(median, range)
20.0 (0.97~109.43) 27.45 (3.56~112.9) 0.184
ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR-TKI
epidermal growth factor receptor tyrosine kinase inhibitor
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ARMS in detecting T790M [24, 25]. More T790M-
positive patients found by more sensitive methods and
the dynamic combination of activating mutation and
T790M mutation could provide more information to
predict the benefits of EGFR-TKI treatment and to
guide subsequent application of third-generation
EGFR-TKI which target both EGFR activating mutation
and T790M mutation. Another limitation was, although
CTONG0901 was a randomized trial, this exploratory
research was based on patients who provided serial
blood samples as scheduled. Therefore, there must be
some selection bias which potentially impacted the
results. The conclusion needs further validation.
Conclusions
In summary, our study suggests that the L858R mutation
population can be divided into two subtypes according
to changes in the plasma L858R mutation. Different dy-
namic types were correlated with different benefits from
EGFR-TKI treatment. Because the difference of L858R
mutation level was found until disease progression,
monitoring the dynamic change of L858R mutation dur-
ing EGFR-TKI treatment had low clinical predictive
value. The molecular mechanisms for the two subtypes
and the impact of plasma L858R level at disease progres-
sion on subsequent treatment strategy needs further ex-
ploration. The optimal strategies to overcome EGFR-TKI
resistance by combining the level of plasma EGFR acti-
vating mutation and resistant genetic information when
disease progressed warrant further investigation.
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all patients. Table S2. Subsequent therapy after EGFR-TKI of two groups.
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patients whose plasma at time of disease progression were with or
without T790M. (DOC 119 kb)
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Table 2 Variants associated with PFS in multivariate Cox
proportional hazards regression model




Adenocarcinoma −1.26 0.54 5.36 0.021 0.285 0.10~0.83
ECOG PS
≥2 1.00
0–1 −1.01 0.53 3.71 0.054 0.363 0.13~1.02
Groups
Stable group 1.00
Ascend group −0.70 0.28 6.43 0.011 0.498 0.30~0.85
PFS progression-free survival, ECOG Eastern Cooperative Oncology Group, PS
performance status
a b
Fig. 3 a Progression-free survival of patients in the ascend group and the stable group. b Overall survival of patients in the ascend group and the stable group
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